Vanessa A. Hayduk

Vanessa A. Hayduk

Auto-generated profile, based on publicly available information

Vanessa A. Hayduk

Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in JMIR Formative Research
Verified
Journal Article
Open access
MGMichael R Gionfriddo
Michael R Gionfriddo
YHYirui Hu
Yirui Hu
BMBhumika Maddineni
Bhumika Maddineni
MKMelissa Kern
Melissa Kern
VHVanessa Hayduk
Vanessa Hayduk
EWEric A Wright
Eric A Wright
Background: Despite routine review of medication lists during patient encounters, patients’ medication lists are often incomplete and not reflective of actual medication use. Contributing to this situation is the challenge of reconciling medication information from existing health records, along with external locations (eg, pharmacies, other provider/hospital records, and care facilities) and patient-reported use. Advances in the interoperability and digital collection of information provides a foundation for integration of these once disparate information sources. Objective: We aim to evaluate the effectiveness of and satisfaction with an electronic health record (EHR)-integrated web-based medication reconciliation application, MedTrue (MT). Methods: We conducted a cluster-randomized controlled trial of MT in 6 primary care clinics within an integrated health care delivery system. Our primary outcome was medication list accuracy, as determined by a pharmacist-collected best-possible medication history (BPMH). Patient and staff perspectives were evaluated through surveys and semistructured interviews. Results: Overall, 224 patients were recruited and underwent a BPMH with the pharmacist (n=118 [52.7%] usual care [UC], n=106 [47.3%] MT). For our primary outcome of medication list accuracy, 8 (7.5%) patients in the MT arm and 9 (7.6%) in the UC arm had 0 discrepancies (odds ratio=1.01, 95% CI 0.38-2.72, P=.98). The most common discrepancy identified was patients reporting no longer taking a medication (UC mean 2.48 vs MT mean 2.58, P=.21). Patients found MT easy to use and on average would highly recommend MT (average net promoter score=8/10). Staff found MT beneficial but difficult to implement. Conclusions: The use of a web-based application integrated into the EHR which combines EHR, patient-reported data, and pharmacy-dispensed data did not improve medication list accuracy among a population of primary care patients compared to UC but was well received by patients. Future studies should address the limitations of the current application and assess whether improved implementation strategies would impact the effectiveness of the application.

2 February 2024 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
JGJove Graham
Jove Graham
SVStephen J. Voyce
Stephen J. Voyce
JHJessica R. Hayden
Jessica R. Hayden
ACAanya Chopra
Aanya Chopra
JTJason Tinsley
Jason Tinsley
EWEric A. Wright
Eric A. Wright
Guideline-directed medical therapies (GDMTs), initiated in-hospital and continued during the transition to outpatient care, are paramount to successful outcomes for patients with acute coronary syndrome (ACS). Incomplete discharge medication prescribing and delayed follow-up lead to worse cardiovascular outcomes. We investigated a system of care using inpatient and outpatient clinical pharmacists to close GDMT gaps, ensure seamless transition to outpatient care, improve patient education, and optimize therapies. We conducted a pre-post cohort analysis of patients with ACS pre- versus post-intervention to compare process metrics and key outcomes using electronic health record data. There were 181 and 135 patients in the pre- and post-intervention cohorts, respectively. Patients post-intervention were significantly more likely to have appropriately-timed follow-up visits scheduled with cardiology (79% vs. 51%, P < 0.0001) and primary care (57% vs. 43%, P = 0.01), to be discharged with prescriptions for P2Y12 inhibitors (87% vs. 64%, P < 0.0001), high dose statins (86% vs. 70%, P = 0.001), and beta blockers (87% vs. 76%, P = 0.01), and significantly less likely to have 30-day all-cause hospital readmissions (4% vs. 12%, P = 0.02) and emergency department (ED) visits (10% vs. 18%, P = 0.04). The integration of advanced practicing pharmacists into a cardiology team at transition and post-hospitalization resulted in improved rates of posthospital follow-up visits, optimization of GDMT medications, and significantly lower 30-day hospital readmission and ED utilization.

29 August 2024 in JMIR Medical Informatics
Verified
Journal Article
Open access
APApoorva Pradhan
Apoorva Pradhan
EWEric A Wright
Eric A Wright
VHVanessa A Hayduk
Vanessa A Hayduk
JBJuliana Berhane
Juliana Berhane
MSMallory Sponenberg
Mallory Sponenberg
SFScott Friedenberg
Scott Friedenberg
Background: Headaches, including migraines, are one of the most common causes of disability and account for nearly 20%‐30% of referrals from primary care to neurology. In primary care, electronic health record–based alerts offer a mechanism to influence health care provider behaviors, manage neurology referrals, and optimize headache care. Objective: This project aimed to evaluate the impact of an electronic alert implemented in primary care on patients’ overall headache management. Methods: We conducted a stratified cluster-randomized study across 38 primary care clinic sites between December 2021 to December 2022 at a large integrated health care delivery system in the United States. Clinics were stratified into 6 blocks based on region and patient-to–health care provider ratios and then 1:1 randomized within each block into either the control or intervention. Health care providers practicing at intervention clinics received an interruptive alert in the electronic health record. The primary end point was a change in headache burden, measured using the Headache Impact Test 6 scale, from baseline to 6 months. Secondary outcomes included changes in headache frequency and intensity, access to care, and resource use. We analyzed the difference-in-differences between the arms at follow-up at the individual patient level. Results: We enrolled 203 adult patients with a confirmed headache diagnosis. At baseline, the average Headache Impact Test 6 scores in each arm were not significantly different (intervention: mean 63, SD 6.9; control: mean 61.8, SD 6.6; P=.21). We observed a significant reduction in the headache burden only in the intervention arm at follow-up (3.5 points; P=.009). The reduction in the headache burden was not statistically different between groups (difference-in-differences estimate –1.89, 95% CI –5 to 1.31; P=.25). Similarly, secondary outcomes were not significantly different between groups. Only 11.32% (303/2677) of alerts were acted upon. Conclusions: The use of an interruptive electronic alert did not significantly improve headache outcomes. Low use of alerts by health care providers prompts future alterations of the alert and exploration of alternative approaches.

17 January 2022 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
LJLaney Jones
Laney Jones
VHVanessa Hayduk
Vanessa Hayduk
KRKatrina M. Romagnoli
Katrina M. Romagnoli
AFAlison Flango
Alison Flango
JMJami Marks
Jami Marks
MGMichael R. Gionfriddo
Michael R. Gionfriddo

2 October 2025 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
RURyley Uber
Ryley Uber
VHVanessa A. Hayduk
Vanessa A. Hayduk
AFAlison Flango
Alison Flango
TWTheron Ward
Theron Ward
LWLeeann Webster
Leeann Webster
EWEric A. Wright
Eric A. Wright

25 March 2024 in JMIR Preprints
Verified
Preprint
Open access
APApoorva Pradhan
Apoorva Pradhan
EWEric A. Wright
Eric A. Wright
VHVanessa A. Hayduk
Vanessa A. Hayduk
JBJuliana Berhane
Juliana Berhane
MSMallory Sponenberg
Mallory Sponenberg
SFScott Friedenberg
Scott Friedenberg
BACKGROUND Headaches including migraines are one of the most common causes of disability and account for nearly 20-30% of referrals from primary care to neurology. Electronic health record-based alerts have been used in the past within primary care with varying degree of success to influence provider behaviors in multiple disease states except for headaches. OBJECTIVE The aim of this project was to evaluate the impact of an electronic alert implemented in primary care on patients’ overall headache management. METHODS We conducted a stratified cluster-randomized study across 38 primary care clinic sites between December 2021 to December 2022 at a large integrated healthcare delivery system in the United States. Clinics were stratified into six blocks based on region and patient-to-provider ratios and then 1:1 randomized within each block into either control or intervention. Providers practicing at intervention clinics received an interruptive alert in the electronic health record. The primary endpoint was a change in headache burden, measured using the Headache Impact Test 6 (HIT-6) scale, from baseline to six months. Secondary outcomes included change in headache frequency and intensity, access to care, and resource utilization. The analysis was performed to assess the difference in difference outcomes between the arms at follow up at the individual patient level. RESULTS We enrolled 203 adult patients with a confirmed headache diagnosis. At baseline the average HIT-6 scores (standard deviation) in each arm were not significantly different (Intervention – 63 (+- 6.9) vs. Control - 61.8 (+- 6.6), P= .21). We observed a significant reduction in the headache burden only in the intervention arm at follow-up (3.5-point, P= .009). The reduction in the headache burden was not statistically different between groups (difference-in-difference estimate: -1.89 (95% confidence interval -5.0, 1.31; P= .25). Similarly, secondary outcomes were not significantly different between groups. Only 11% of alerts were acted upon. CONCLUSIONS The use of an interruptive electronic alert did not significantly improve headache outcomes. Low use of alerts by providers prompts future alterations of the alert and exploration of alternative approaches. CLINICALTRIAL Registered at clinicaltrials.gov as registration number NCT05067725.